This website uses cookies to enhance the user experience.
P

PLASMACUTE AS984 648 812

Research
Limited company
c/o Complér Accounting AS Vestre Strømkaien 7 5008 BERGEN, Norge

PLASMACUTE AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

Chairman of the board
Years since formation
23 years
since Jul 1, 2002
Type
Limited company
VAT registered
No
Number of employees
0

Ownership

Number of shares and share classes
220,000
1 share class
Total number of shareholders
3
1 company, 2 persons
Belongs to group of

Financials

Annual total result 2023
-8,826,922
NOK
Total equity 2023
-40,784,582
NOK
Last update: Oct 24, 2024

Management

Board

NameRoleShares
Contact Person, Chairman
28.13 %
directly 4.55 %
indirectly 23.59 %
Alternate Member
27.27 %
indirectly

Others

NameRoleShares
C
COLLEGIUM REVISJON AS
Auditor-
C
COMPLÉR ACCOUNTING AS
Accountant-

Top 10 individual shareholders

NameRoleShares
Contact Person, Chairman
28.13 %
directly 4.55 %
indirectly 23.59 %
Alternate Member
27.27 %
indirectly
-
22.73 %
directly 4.55 %
indirectly 18.18 %
-
7.29 %
indirectly
-
7.29 %
indirectly
Last update: Nov 9, 2023

Ownership

Company shareholders

NameShare classNumber of sharesShare
M
MEDICI HOLDING AS
Ordinary shares
200,000
90.91 %
Ordinary shares
10,000
4.55 %
Ordinary shares
10,000
4.55 %

Shares owned by the PLASMACUTE AS

NameShare classNumber of sharesShare
L
LIFE BEAT NORGE AS
Ordinary shares
3,000
100 %
D
DEEPX HEALTH AS
NO0010159700
20,368,187
31.77 %
Last update: May 24, 2024

Group structure

  • Total operating income 2023: NOK 0
    Operating profit 2023: NOK -82,744
    Employees: 0

Financials

in NOK

Summary

Year202320222021
Total operating income
0
210,799
258,508
Annual Total Result
-8,826,922
-1,574,923
-1,350,867
Total assets
21,061,523
44,890,155
43,959,241
Total liabilities
61,846,105
77,484,198
75,891,129
Total equity
-40,784,582
-32,594,043
-31,931,888

P&L

Year202320222021
Total operating income
0
210,799
258,508
Total operating costs
67,083
276,446
339,580
Operating result
-67,083
-65,647
-81,072
Financial income/costs
-8,759,839
-1,509,276
-1,269,795
Profit before tax
-8,826,922
-1,574,923
-1,350,867
Total tax & extraordinary income/cost
0
0
0
Annual Total Result
-8,826,922
-1,574,923
-1,350,867

Balance overview

Year202320222021
Total fixed assets
20,368,188
43,832,051
38,832,052
Total current assets
693,335
1,058,104
5,127,189
Total assets
21,061,523
44,890,155
43,959,241
Short term debt
37,147,408
52,785,501
51,192,432
Long term debt
24,698,697
24,698,697
24,698,697
Total liabilities
61,846,105
77,484,198
75,891,129
Contributed capital
4,340,908
3,704,524
2,791,757
Retained earnings
-45,125,490
-36,298,567
-34,723,645
Total equity
-40,784,582
-32,594,043
-31,931,888
Total equity and liabilities
21,061,523
44,890,155
43,959,241

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology